Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

161. Anticoagulant treatment for subsegmental pulmonary embolism. (Abstract)

Anticoagulant treatment for subsegmental pulmonary embolism. Acute pulmonary embolism (PE) is a common cause of death, accounting for 50,000 to 200,000 deaths annually. It is the third most common cause of mortality among the cardiovascular diseases, after coronary artery disease and stroke.The advent of multi-detector computed tomographic pulmonary angiography (CTPA) has allowed better assessment of PE regarding visualisation of the peripheral pulmonary arteries, increasing its rate (...) imaging performed for other reasons (for example routine CT for cancer staging in oncologic patients).Traditionally, all PEs are anticoagulated in a similar manner independent of the location, number and size of the thrombi. It has been suggested that many patients with SSPE may be treated without benefit, increasing adverse events by possible unnecessary use of anticoagulants.Patients with isolated SSPE or incidental PE may have a more benign clinical presentation compared with those with proximal

2016 Cochrane

162. Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai Full Text available with Trip Pro

Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai To summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China.Non-valvular atrial fibrillation (NVAF)-associated stroke patients were prospectively registered as an electronic database. Use rate of antithrombotics (...) rates of warfarin, DE, and antiplatelets were 20.8% (15/72), 12.5% (9/72), and 43.1% (31/72). The DE did not improve use of anticoagulants (P = 0.639). There were 19 (17.3%) recurrent ischemic stroke events up to October 2015; two (9.5%) in the non-user group, 10 (18.5%) in the antiplatelet group, and seven (20.0%) in the anticoagulants group (P = 0.570). Furthermore, recurrence rates were similar between the DE group (20.0%) and the Warfarin group (20.0%, P = 1.000). The most common reason

2016 Chronic diseases and translational medicine

163. Bridging Anticoagulation in Patients with Atrial Fibrillation. (Abstract)

Bridging Anticoagulation in Patients with Atrial Fibrillation. 26736004 2016 01 08 2018 12 02 1533-4406 374 1 2016 01 07 The New England journal of medicine N. Engl. J. Med. Bridging Anticoagulation in Patients with Atrial Fibrillation. 93-4 10.1056/NEJMc1513255 Douketis James D JD Hasselblad Vic V Ortel Thomas L TL eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Heparin, Low-Molecular-Weight AIM IM N Engl J Med. 2016 Jan 7;374(1):90-1 26736005 N Engl J Med (...) . 2016 Jan 7;374(1):91 26736006 N Engl J Med. 2016 Jan 7;374(1):91-2 26736007 N Engl J Med. 2016 Jan 7;374(1):92 26736008 N Engl J Med. 2016 Jan 7;374(1):92-3 26736009 N Engl J Med. 2015 Aug 27;373(9):823-33 26095867 Anticoagulants administration & dosage Atrial Fibrillation drug therapy Elective Surgical Procedures Female Heparin, Low-Molecular-Weight administration & dosage Humans Male Thromboembolism prevention & control 2016 1 7 6 0 2016 1 7 6 0 2016 1 9 6 0 ppublish 26736004 10.1056/NEJMc1513255

2016 NEJM

164. Bridging Anticoagulation in Patients with Atrial Fibrillation. Full Text available with Trip Pro

Bridging Anticoagulation in Patients with Atrial Fibrillation. 26736005 2016 01 08 2018 12 02 1533-4406 374 1 2016 01 07 The New England journal of medicine N. Engl. J. Med. Bridging Anticoagulation in Patients with Atrial Fibrillation. 90-1 10.1056/NEJMc1513255 Duca Andrea A Jagoda Andy A eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Heparin, Low-Molecular-Weight AIM IM N Engl J Med. 2016 Jan 7;374(1):93-4 26736004 N Engl J Med. 2015 Aug 27;373(9):823-33 (...) 26095867 Anticoagulants administration & dosage Atrial Fibrillation drug therapy Elective Surgical Procedures Female Heparin, Low-Molecular-Weight administration & dosage Humans Male Thromboembolism prevention & control 2016 1 7 6 0 2016 1 7 6 0 2016 1 9 6 0 ppublish 26736005 10.1056/NEJMc1513255 10.1056/NEJMc1513255#SA1

2016 NEJM

165. Bridging Anticoagulation in Patients with Atrial Fibrillation. Full Text available with Trip Pro

Bridging Anticoagulation in Patients with Atrial Fibrillation. 26736006 2016 01 08 2018 12 02 1533-4406 374 1 2016 01 07 The New England journal of medicine N. Engl. J. Med. Bridging Anticoagulation in Patients with Atrial Fibrillation. 91 10.1056/NEJMc1513255 Vink Roel R Sohne Maaike M Huisman Menno V MV eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Heparin, Low-Molecular-Weight AIM IM N Engl J Med. 2016 Jan 7;374(1):93-4 26736004 N Engl J Med. 2015 Aug (...) 27;373(9):823-33 26095867 Anticoagulants administration & dosage Atrial Fibrillation drug therapy Elective Surgical Procedures Female Heparin, Low-Molecular-Weight administration & dosage Humans Male Thromboembolism prevention & control 2016 1 7 6 0 2016 1 7 6 0 2016 1 9 6 0 ppublish 26736006 10.1056/NEJMc1513255 10.1056/NEJMc1513255#SA2

2016 NEJM

166. Bridging Anticoagulation in Patients with Atrial Fibrillation. Full Text available with Trip Pro

Bridging Anticoagulation in Patients with Atrial Fibrillation. 26736007 2016 01 08 2018 12 02 1533-4406 374 1 2016 01 07 The New England journal of medicine N. Engl. J. Med. Bridging Anticoagulation in Patients with Atrial Fibrillation. 91-2 10.1056/NEJMc1513255 Caldeira Daniel D Costa Joao J Ferreira Joaquim J JJ eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Heparin, Low-Molecular-Weight AIM IM N Engl J Med. 2016 Jan 7;374(1):93-4 26736004 N Engl J Med (...) . 2015 Aug 27;373(9):823-33 26095867 Anticoagulants administration & dosage Atrial Fibrillation drug therapy Elective Surgical Procedures Female Heparin, Low-Molecular-Weight administration & dosage Humans Male Thromboembolism prevention & control 2016 1 7 6 0 2016 1 7 6 0 2016 1 9 6 0 ppublish 26736007 10.1056/NEJMc1513255 10.1056/NEJMc1513255#SA3

2016 NEJM

167. Bridging Anticoagulation in Patients with Atrial Fibrillation. Full Text available with Trip Pro

Bridging Anticoagulation in Patients with Atrial Fibrillation. 26736008 2016 01 08 2018 12 02 1533-4406 374 1 2016 01 07 The New England journal of medicine N. Engl. J. Med. Bridging Anticoagulation in Patients with Atrial Fibrillation. 92 10.1056/NEJMc1513255 Arbit Boris B Padwal Jennifer J Hsu Jonathan J eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Heparin, Low-Molecular-Weight AIM IM N Engl J Med. 2016 Jan 7;374(1):93-4 26736004 N Engl J Med. 2015 Aug (...) 27;373(9):823-33 26095867 Anticoagulants administration & dosage Atrial Fibrillation drug therapy Elective Surgical Procedures Female Heparin, Low-Molecular-Weight administration & dosage Humans Male Thromboembolism prevention & control 2016 1 7 6 0 2016 1 7 6 0 2016 1 9 6 0 ppublish 26736008 10.1056/NEJMc1513255 10.1056/NEJMc1513255#SA4

2016 NEJM

168. Bridging Anticoagulation in Patients with Atrial Fibrillation. Full Text available with Trip Pro

Bridging Anticoagulation in Patients with Atrial Fibrillation. 26736009 2016 01 08 2018 12 02 1533-4406 374 1 2016 01 07 The New England journal of medicine N. Engl. J. Med. Bridging Anticoagulation in Patients with Atrial Fibrillation. 92-3 10.1056/NEJMc1513255 Clapin Alexis A eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Heparin, Low-Molecular-Weight AIM IM N Engl J Med. 2016 Jan 7;374(1):93-4 26736004 N Engl J Med. 2015 Aug 27;373(9):823-33 26095867 (...) Anticoagulants administration & dosage Atrial Fibrillation drug therapy Elective Surgical Procedures Female Heparin, Low-Molecular-Weight administration & dosage Humans Male Thromboembolism prevention & control 2016 1 7 6 0 2016 1 7 6 0 2016 1 9 6 0 ppublish 26736009 10.1056/NEJMc1513255 10.1056/NEJMc1513255#SA5

2016 NEJM

169. Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature Full Text available with Trip Pro

Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature Hair loss is associated with the anticoagulants heparin and warfarin. With the recent availability of direct oral anticoagulants (DOACs) it is of clinical interest to know if they are implicated with hair loss and/or whether they could be successfully prescribed for patients who suffer from coumarin- or heparin-related alopecia. Initially reports of heparin- and coumarin-associated (...) alopecia available through PubMed and Medline were explored in order to establish the cause of this side effect. Currently there is a lack of unanimity on why anticoagulants cause alopecia. However, timing and presentation strongly suggest that telogen effluvium is part of the process. The observation that both heparins and coumarins cause a similar pattern of hair loss suggests a shared mechanism related to anticoagulant activity. To date, the World Health Organization has received 405 reports of DOAC

2016 Drugs - real world outcomes

170. Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation | CADTH.ca Find the information you need Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation Last updated: March 31, 2016 Project Number: HT0005-TR0005 Product (...) Line: Technology Review Result type: Report Venous thromboembolic events (VTEs) include both deep vein thrombosis (DVT) and pulmonary embolism (PE). VTEs represent an important disease burden in Canada; they are common and likely to increase as the population ages. The standard of care for patients diagnosed with DVT and/or PE has been systemic anticoagulation with heparin (low-molecular-weight heparin [LMWH], administered subcutaneously), followed by oral administration of vitamin K antagonists

2016 CADTH - Technology Review

171. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants

Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu http://dx.doi.org/10.1055/s-0042-102652 Endoscopy 2016; 48: 1–18 © Georg Thieme Verlag KG Stuttgart· New

2016 European Society of Gastrointestinal Endoscopy

172. Patient self-monitoring oral anticoagulation therapy

Patient self-monitoring oral anticoagulation therapy evidence note Update of evidence note 50 Number 57 November 2015 Is patient self-monitoring (including self-testing and self- management) of oral anticoagulation therapy safe, efficacious and cost-effective? What is an evidence note Evidence notes are rapid reviews of published secondary clinical and cost-effectiveness evidence on health technologies under consideration by decision-makers within NHSScotland. They are intended to provide (...) strategy when compared with usual care. However, further analyses demonstrated that, although self-management was cost- effective, self-testing was not. It is worth noting that cost effectiveness of self-management is based on the assumption that it leads to a reduction in thromboembolic events. ? The findings support the view that the cost effectiveness of self-monitoring is strongly contingent on the patient being able to manage their own oral anticoagulation therapy. By doing so, this helps

2016 Evidence Notes from Healthcare Improvement Scotland

173. Cohort study: Restarting oral anticoagulation among patients with atrial fibrillation with gastrointestinal bleeding was associated with lower risk of all-cause mortality and thromboembolism

Cohort study: Restarting oral anticoagulation among patients with atrial fibrillation with gastrointestinal bleeding was associated with lower risk of all-cause mortality and thromboembolism Restarting oral anticoagulation among patients with atrial fibrillation with gastrointestinal bleeding was associated with lower risk of all-cause mortality and thromboembolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can (...) anticoagulation among patients with atrial fibrillation with gastrointestinal bleeding was associated with lower risk of all-cause mortality and thromboembolism Article Text Prognosis Cohort study Restarting oral anticoagulation among patients with atrial fibrillation with gastrointestinal bleeding was associated with lower risk of all-cause mortality and thromboembolism Waqas T Qureshi 1 , Usama Nasir 2 Statistics from Altmetric.com Commentary on : Staerk L , Lip GY , Olesen JB , et al . Stroke and recurrent

2016 Evidence-Based Medicine

174. Anticoagulation therapy guidelines for open heart mechanical valve replacement patients

Anticoagulation therapy guidelines for open heart mechanical valve replacement patients Anticoagulation therapy guidelines for open heart mechanical valve replacement patients Anticoagulation therapy guidelines for open heart mechanical valve replacement patients Mitchell, MD, Cardona, LA, Herrmann, HC, Szeto, WY, Mull, N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Mitchell, MD, Cardona, LA, Herrmann, HC, Szeto, WY, Mull, N. Anticoagulation therapy guidelines for open heart mechanical valve replacement patients. Philadelphia: Center for Evidence-based Practice (CEP). 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Cardiac Surgical Procedures; Humans; Thrombolytic Therapy Language Published English Country of organisation United States English summary An English language summary is available. Address

2016 Health Technology Assessment (HTA) Database.

175. Are New Oral Anticoagulants Safer Than Vitamin K Antagonists in the Treatment of Venous Thromboembolism?

Are New Oral Anticoagulants Safer Than Vitamin K Antagonists in the Treatment of Venous Thromboembolism? TAKE-HOME MESSAGE Patients with acute venous thromboembolism treated with new oralanticoagulants have similar rates of recurrent venous thromboembolism and death as those treated with warfarin. Although new oral anticoagulants are associated with a lower incidence of major bleeding, there may be an increased incidence of myocardial infarction. Are New Oral Anticoagulants Safer Than Vitamin K (...) and the other 2 receiving a score of 4. Commentary The vitamin k antagonist warfarin has been the cornerstone of anti- coagulation therapy for the past 50 years. Although an effective anticoagulant, it has several limi- tations, including interactions with multiple medications and foods, genetic polymorphisms, and the need for frequent inter- national normalized ratio moni- toring. In addition, warfarin is initially prothrombotic and so may require bridging with another anticoagulant. Because

2016 Annals of Emergency Medicine Systematic Review Snapshots

176. New/Novel Oral Anticoagulants (NOACs): Management of Bleeding

New/Novel Oral Anticoagulants (NOACs): Management of Bleeding © 2016 Thrombosis Canada Page 1 of 1 NOVEL ORAL ANTICOAGULANTS (NOACS): MANAGEMENT OF BLEEDING OBJECTIVE: To assist clinicians in the management of bleeding in patients receiving direct oral anticoagulants (NOACs). BACKGROUND: Two oral Factor Xa inhibitors (apixaban and rivaroxaban) and an oral thrombin inhibitor (dabigatran) are approved for clinical use in Canada based on findings from large randomized trials. Like all other (...) anticoagulants, bleeding is the major complication of therapy. Specific antidotes for these drugs are expected to be available soon. Studies of successful reversal strategies using non-specific products in patients with bleeding have not been reported. Appropriate management in all cases of bleeding requires a systematic approach to assessing the competing risks and consequences of bleeding and thrombosis. MANAGEMENT OF BLEEDING EPISODES Minor Bleeding e.g. anterior epistaxis, hemorrhoid bleeding

2016 Thrombosis Interest Group of Canada

177. Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning Full Text available with Trip Pro

Unplanned pregnancy on a direct oral anticoagulant (Rivaroxaban): A warning Direct oral anticoagulants (DOACs or NOACs -non-vitamin K oral anticoagulants), as the name suggests, are oral anticoagulants with a direct inhibitory action either against factor X or factor II (thrombin). Pregnant women were excluded from participating in all the large trials of the DOACs and they are considered contra-indicated in pregnancy and breast feeding. We present a case of inadvertent exposure to rivaroxaban

2015 Obstetric medicine

178. Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation

Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend (...) Safety & Emergency Services theme_10_collection theme_10_frontend theme_10_collection theme_10_frontend Sports, Recreation, Arts & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation Effective Date

2015 Clinical Practice Guidelines and Protocols in British Columbia

179. Oral anticoagulation with vitamin K antagonist therapy

Oral anticoagulation with vitamin K antagonist therapy File name: 20151202 AS OAC v1.0.docx Version: 1.0 Date: 22 January 2016 Produced by: SHTG Page: 1 Review date: December 2017 Advice Statement 003/2015 December 2015 Is patient self-monitoring (including self- testing and self-management) of oral anticoagulation with vitamin K antagonist therapy safe, efficacious and cost-effective? This advice has been produced following completion of evidence note 57 by Healthcare Improvement Scotland (...) then decides on dose adjustment. In patient self-management the patient not only performs the blood sampling and analysis but also makes any vitamin K antagonist dose adjustment required. Clinical effectiveness and safety of anticoagulation monitoring ? Meta-analyses of data from mainly low quality randomised controlled trials in patients receiving long-term oral anticoagulation therapy with vitamin K antagonists consistently report that self-monitoring of INR reduces the incidence of thromboembolic events

2015 SHTG Advice Statements

180. The future of anticoagulation management in atrial fibrillation in Europe: An assessment of today's challenges with recommendations for the future Full Text available with Trip Pro

The future of anticoagulation management in atrial fibrillation in Europe: An assessment of today's challenges with recommendations for the future Atrial fibrillation (AF) is the most common type of cardiac arrhythmia, affecting approximately 1-2 per cent of the population worldwide. Those who suffer from AF have a five times higher risk of stroke. AF prevalence increases with age and it affects roughly 18 per cent of the population over 85. Consequently, as populations age, AF is becoming (...) management in Europe, with a focus on the use of anticoagulants in the prevention of AF-related stroke. Through rapid evidence assessment, key informant interviews, PESTLE analysis and the development and exploration of future scenarios, we have developed sets of shorter- and longer-term recommendations for improving AF-related patient outcomes. The short-term recommendations are: i) improve AF awareness among the public and policymakers; ii) support education about AF management for healthcare

2015 Rand health quarterly